ALEC Alector Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALEC

Price (delayed)

$6.01

Market cap

$499M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.62

Enterprise value

$386.53M

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system ...

Highlights
The quick ratio has soared by 61% from the previous quarter and by 43% YoY
The debt has contracted by 9% YoY and by 2.5% from the previous quarter
ALEC's gross profit is down by 35% YoY
The revenue has declined by 35% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://alector.com
Peers: OVID

Key stats

What are the main financial stats of ALEC
Market
Shares outstanding
83.03M
Market cap
$499M
Enterprise value
$386.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.32
Price to sales (P/S)
3.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.89
Earnings
Revenue
$133.62M
EBIT
-$130.06M
EBITDA
-$121.58M
Free cash flow
-$24.45M
Per share
EPS
-$1.62
Free cash flow per share
-$0.3
Book value per share
$2.59
Revenue per share
$1.62
TBVPS
$9.55
Balance sheet
Total assets
$787.65M
Total liabilities
$573.21M
Debt
$43.33M
Equity
$214.44M
Working capital
$632.63M
Liquidity
Debt to equity
0.2
Current ratio
7.74
Quick ratio
7.64
Net debt/EBITDA
0.93
Margins
EBITDA margin
-91%
Gross margin
100%
Net margin
-99.8%
Operating margin
-103.2%
Efficiency
Return on assets
-15.4%
Return on equity
-52.1%
Return on invested capital
-24.4%
Return on capital employed
-18.7%
Return on sales
-97.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALEC stock price

How has the Alector stock price performed over time
Intraday
-2.28%
1 week
-6.82%
1 month
-35.45%
1 year
-60.46%
YTD
-34.89%
QTD
-34.89%

Financial performance

How have Alector's revenue and profit performed over time
Revenue
$133.62M
Gross profit
$133.62M
Operating income
-$137.83M
Net income
-$133.31M
Gross margin
100%
Net margin
-99.8%
ALEC's gross profit is down by 35% YoY
The revenue has declined by 35% year-on-year
The net margin has grown by 2.6% from the previous quarter
Alector's net income has increased by 2.3% QoQ

Growth

What is Alector's growth rate over time

Valuation

What is Alector stock price valuation
P/E
N/A
P/B
2.32
P/S
3.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.89
ALEC's EPS is up by 3% from the previous quarter
ALEC's P/B is 53% below its 5-year quarterly average of 5.0 and 32% below its last 4 quarters average of 3.5
The equity has decreased by 29% YoY and by 15% QoQ
The stock's price to sales (P/S) is 91% less than its 5-year quarterly average of 40.0 and 22% less than its last 4 quarters average of 4.9
The revenue has declined by 35% year-on-year

Efficiency

How efficient is Alector business performance
Alector's ROA has plunged by 166% YoY
The return on invested capital has dropped by 102% year-on-year but it has grown by 12% since the previous quarter
The return on equity has declined by 6% since the previous quarter
ALEC's ROS is up by 3.3% from the previous quarter

Dividends

What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALEC.

Financial health

How did Alector financials performed over time
ALEC's total assets is 37% greater than its total liabilities
The quick ratio has soared by 61% from the previous quarter and by 43% YoY
Alector's current ratio has soared by 61% from the previous quarter and by 44% YoY
The debt is 80% less than the equity
The equity has decreased by 29% YoY and by 15% QoQ
The debt to equity is up by 25% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.